Connect your AI

Tango Therapeutics TNGX Price / sales

Price / sales at other companies

Bristol-Myers SquibbBMY

2.6×-0.1×

AmgenAMGN

5.1×+0.2×

Gilead SciencesGILD

5.8×+1.0×

ExelixisEXEL

4.8×+0.3×

CG OncologyCGON

1,126.9×-1,693×

Lantheus HoldingsLNTH

3.2×-1.2×

Other financials

Income statement

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

Market cap$4.55B+1,915%

Enterprise value$4.43B+2,204%

Profitability

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

market cap/total revenue=52.4×

Based on the most recent quarter.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Tango Therapeutics's price / sales?: Tango Therapeutics (TNGX) reported price / sales of 52.4× in Q1 2026.
How has Tango Therapeutics's price / sales changed year-over-year?: Tango Therapeutics's price / sales increased by 1349.6% year-over-year, from 3.6× to 52.4×.
What is the long-term trend for Tango Therapeutics's price / sales?: Over 4 years (2021 to 2025), Tango Therapeutics's price / sales has grown at a -7.3% compound annual growth rate (CAGR), from 25.9× to 19.1×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.